Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree!
If you are long here then you don't need immediate gratification. If you're not, then I don't really care....
You just made my point! This isn't a toy that needs to be marketed, its a valuable stock that people of interest will find after production has begun. As for you wrighting (writing) a book, I suggest you hire a ghost writer!
yipee, then you should be thrilled with where it is right now!
I've been here WAY longer than you have - I was in at .004! Investor relations is not being beholden to the insecurities of investors!!
Their job is to produce gold, not hold your hand!!!
Gee, I would much rather the people running mining operations know how to run a mine than having them care about stockholder paranoia!! The end=game is them getting gold out of the land, not communicating with the stockholders!!!!
The amount of hand-holding necessary here by management is absolutely amazing to me! Why don't you just let them do their jobs and stop calling for their resignation. If you didn't like the company or do your DD (they don't release fluff PR's) then why did you invest. I've been here a LONG time and am happy about what is going on and where management is taking us. If you're looking for daily fluff then this is NOT the stock to be in! However, if you are patient, there is a great reward ahead.
Thanks Dunphy!!!
From the most recent 10-K
"(b) Holders. As of March 15, 2011, our Common Stock was held by approximately 506 shareholders of record"
Email, but I suspect it is also up on their website.
edit: it is http://www.cordblood-america.com/investors/ir-blog/206-cbai-business-valuation
Cord Blood America (OTC BB: CBAI) CEO Matthew Schissler Explains Business Model
CBAI Business Valuation Blog April 8, 2011
My Fellow Shareholders:
Below is an executive summary of CBAI's business model:
Cord Blood America, Inc. (CBAI's) core business is focused on the cryogenic preservation of umbilical cord blood stem cells for families (private banking) and has achieved rapid growth in its first 8 years of operation with revenues exceeding $3.24 million in 2009, and $4.1M for 2010. The company's strategy for growth thus far has been a two-pronged attack; accretive acquisitions and focused organic operations. CBAI is confident that this strategy will continue to provide ample opportunities for the organization to capitalize on expanding its place amongst the leaders in the dynamic field of stem cells.
The business model for umbilical cord blood storage is both simple to understand yet attractive due to its recurring revenue streams for storage services. The practice is for parents to pay for the collection, processing and first year's storage at the time of the child's birth, with an annual storage payment made each year thereafter, for an additional 18 years. Under the current business model, each new storage agreement yields an ever increasing gross margin coupled with a less than 1% per year client churn rate providing a steady, highly profitable annuity based financial model.
The Company believes strongly that the current and future prospects for the operation are bright, with three acquisitions under LOI that would change our revenues from $4M to over $20M, while taking the company from losing money, to the ability to operate off its own cash flow.
CURRENT OPERATIONAL PERFORMANCE
CBAI has made significant changes in its operations since the beginning of calendar year 2010.
First, CBAI focused its effort on streamlining its cord blood banking operation by better aligning revenue opportunities with infrastructure requirements. The CBAI subsidiary that is the day to day client facing business unit for umbilical cord blood banking is CorCell Companies, Inc. Highlights from this strategy implementation are:
Ø Opened a state of the art 17,000 square foot facility for processing and storage of stem cells. This reduced our overall costs significantly as we used to outsource lab services.
Ø Acquired 50.1% of the third largest cord blood bank in Germany, 50.1% of the 2nd largest cord blood bank in Argentina, and invested a minority stake in a cord blood banking company in both China, and Spain.
Ø Over 25K client sample base generating referral sales of approximately 40% of all sales.
Ø Added 3 new insurance contracts (11 total now), and signed exclusive agreements with the NLO and AHIP to increase organic growth.
Ø Yearly "new" revenue generation of approximately $2.5 Million per annum with 61% Gross Margin.
The company also maintains all billing and collection of samples and is staffed by corporate resources dedicated to billing and receivables management for annual storage services. Collectively these storage only services drive an additional $1.7 Million in annual revenues.
The net effect of these actions has been a significant reduction in the cash burn of the business.
ACQUISITIONS UNDER LOI
CBAI has three acquisitions under LOI that would drive revenues north of $20M per annum, and have operational cash flow north of $3M starting in 2012.
Ø Largest cord blood bank in Mexico with revenues north of $7M per year
Ø Largest Cord Blood bank in South America, with revenues north of $4M a year
Ø Cellular Therapeutics and Storage Company in United States with over $10M in revenue
Cord Blood banks are valued mostly on their assets under management. Each asset, a storage contract of 18 years with an average of over $100 per year can result in a cash value today of around $1,000 if fully recognized. Some companies in the industry have sold for as high as $2300 per asset. The net effect of these acquisitions would be operational cash flow, profitability and over $150M worth of assets in cryogenic storage. These three acquisitions are a complete "game changer" for CBAI. Acquiring any one of the three pushes us over the operating cash flow line in a short period of time.
The advantages to CBAI to do these are:
Ø CBAI is cash flow positive immediately. This is most significant in that the company can stand on its own without the need for additional working capital. The ongoing evaluation of funding options has led to further dilution of the stock.
Ø The value of the company continues to grow every day as new sales are added. The ability to operate the organization on its own cash and with the compounding effect of multiple years of new business creates even larger multiples on the valuation go forward.
Ø The remaining debt holders are paid down. Once those obligations are cleared, which CBAI estimates can occur immediately with the proposed financing, the financial picture for the company reaches yet another milestone. Consider zero or nominal long term debt and an annuity based business model with at least a 17 year horizon.
Ø The ability to expand into the current cord blood space and the adipose (adult) stem cell space. CBAI can provide additional details regarding this venture but the company has had material discussions with intellectual property leaders in this space that will add valuable revenue streams in the years ahead.
For the investor making this investment in CBAI, the advantages are:
Ø Long term annuity. The company has proven since March 2007 the recurring revenue consistency behind a large sample base. CBAI can demonstrate the long term cash flows from those samples and know that they more than adequately cover the up-front investment.
Ø Stock appreciation. For the same reasons mentioned above in the advantages for CBAI, we believe our investor will recognize the increase in their equity stake.
While valuation models will vary based on each parties weight to various risk factors, consider that if CBAI never made another umbilical cord blood unit sale after completion of the proposed acquisitions, the net present value for the gross margin of current sample base realistically would range from $120 to $150 million dollars. The ability to compound that return through the continuing sale of annuity based processing and storage agreements only magnifies the return potential of this business model.
Some statements made in this Company Presentation are forward looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
What and where did people receive?
Majority of their shares are held by insiders and the have extremely low volume every day.
We NEED an R/S folks in order to make this more of an attractive investment for other people - what we DON'T need is further dilution of our investment. I've already voted with my 2+ million shares, and I encourage you to do the same. Vote YES on the R/S and NO on the A/S increase.
There IS another option!!
Everyone does know that it's a 2-part vote, right???
First part is on the R/S, second is on the A/S increase. You CAN vote yes on the R/S and no on the A/S - seems like a logical plan to increase the pps and not allow more dilution.....
Management's JOB is not to hold the hand of nervous shareholders, or to worry on a daily basis about the PPS. Their JOB is to produce gold, after that everything else will take care of itself!
Not for SMAS, but for the CEO. Will have to wait till then.
4/14 is a big day...
Speak English newbie, the longs are VERY happy with where we are at PCFG and where we are going!
How 'ya feeling about the day now?? LOL
Of course not, what scam ever costs anyone any money? SMAS is a scam, make no mistake about it.
Check the court dockets - SMAS is a dead stock!!
I know the CEO will be in jail long before this stock ever breathes a sigh of life.
Check the court dockets - SMAS is a dead stock!!
NO DILUTION!!!!!
This is not speculation about the CEO of SMAS, it is fact, and can be found in the court dockets. IMO, there is nothing but a black hole in the stock of this company and anyone risking their money here should think three times about their potential purchase.
You never know about SMAS, they could scam a new group of "investors" to buy their stock, you are correct! I can tell you that they have lost court judgements and have to make payments which have not been, made or the CEO will be tried with contempt of court and be jailed.
Actually, if you look at the details of that trade, SMAS traded at a value of less than .0001, which would be a dump of shares by the CEO, likely trying to pay the rent or some other bill.
"As recently as December", 3 months ago by the way, would also indicate that SMAS has no interest or value.
Technically, SMAS cannot be traded in the open market per the below.
There are no market makers in this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey marketsecurities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and Best Execution of orders is difficult.
I agree, and I'm not the one who brought the spelling up as an issue. Financial markets in the US spell it as GREY, whether or not it is generically spelled differently in any particular country. Point is, SMAS is a worthless stock and company which has more debt than it can possibly pay, and with no discernible income.
SMAS trades on the GREY market as it's classified in the US. It's a dead stock with no value.
If you really want to use Wikipedia as your definitive source of accurate information?
But hey, if you do, here's a wiki entry...... You do realize it is freely added to by ANYONE, right?
Grey Market
Securities that are not listed on any stock exchange nor formally quoted via the OTCBB or Pink Sheets are considered to be in the Grey Market. Unsolicited transactions are processed independently and not centrally listed or quoted. Trades are reported to a Self-regulatory organization (SRO), which then passes the data on to market data companies.
http://en.wikipedia.org/wiki/Pink_Sheets
But I would trust http://www.otcmarkets.com/learn/otc-market-tiers much more than a wiki!
WRONG! But nice attempt to correct my spelling.
There are no market makers in this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and Best Execution of orders is difficult.
http://www.otcmarkets.com/learn/otc-market-tiers
BUYER BEWARE!!!! These fees are just to get current!
Calculate Annual List of Officer Fees for
SOMATIC SYSTEMS, INC.
Item Fee
Annual List (due 3/31/2010) File This List Online Now! File Offline
$ 10,825.00
Annual List Late Fee $ 75.00
Annual List (due 3/31/2011) File This List Online Now! File Offline
$ 10,825.00
TOTAL*
$ 21,725.00
* These fees are current as of today's date of 03/02/2011 16:42 PM but can change based on events occurring on future dates and do not include the state business license fee. Calculated fees do not include fees and penalties if the entity is in default or revoked status due to resignation or other registered agent deficiency or is on administrative hold. For these types of inquiries please contact our office.
http://nvsos.gov/sosentitysearch/FeeDetails.aspx?ctok=fQOStC%252bQghjldMacI8yxXw%253d%253d
EVERYONE KNOWS, this stock and company have NO value. It hasn't traded off of the grey market for over a year!!!
Which day WERE you talking about, because Stevie Wonder has just 2 days left to make payment before he's charged with contempt of court and subject to jail.... Anyone who buys this crap stock is just being silly - STAY AWAY!!!!
I'd go one step further and tell him you're an investor. He'd likely be more inclined to give you a tour if he knows you've got money in the company! We know that they are working toward production, so there's no inside information to be garnered by seeing that what they've already announced is happening.
May be an off-the-wall opinion, but I think if you were to contact Mitch and tell him that you were coming up, he might actually show you around and LET you take pictures. I'm not of the opinion that a clandestine operation is necessary.
Or, maybe the reason the accounting is taking so long is that they are thinking big, as I am. A move to the BB will do little if nothing to the pps - however, accounting done, production announced at $xx/mo, and this will fly to over $2 in a month. Then a REAL uplist!